Representative Matters
REFERENZMANDATE
代表事项
IPOs and Capital Markets:
- HOOKIPA Pharma (Austria) in its $84 million initial public offering
- BioDelivery Sciences International in its $60 million follow-on public offering
- CRISPR Therapeutics (Switzerland) in its $97 million initial public offering and concurrent private placement, $200 million and $130 million public follow-on offerings
- Broadfin Capital on its investment in BioDelivery Sciences International’s $50 million follow-on public offering
- Surface Oncology in its $119.5 million initial public offering
- Goldman Sachs as lead underwriter in Arvinas’ $120 million initial public offering
- Ra Pharmaceuticals in its $58 million public follow-on offering
Joint Ventures, M&A and Collaborations
- BlueRock Therapeutics on its agreement to be fully acquired by Bayer AG for up to $1 billion
- Ginkgo Bioworks on its collaboration with Synlogic, Inc. (Nasdaq: SYBX) to accelerate the expansion and development of Synlogic’s pipeline of Synthetic Biotic medicines using Ginkgo’s cell programming platform
- CRISPR Therapeutics (Switzerland) in an expanded collaboration with Vertex Pharmaceuticals to enhance its gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1
- Arvinas, Inc. on an agreement with Bayer to jointly launch a new company to leverage Arvinas’ PROTAC technology for agricultural applications
- BioDelivery Sciences International in its acquisition of U.S. commercial rights to Symproic from Shionogi
- ProKidney and its lead investor, Pablo Legorreta, founder and CEO of Royalty Pharma, in the acquisition of inRegen and Twin City Bio LLC for $62 million
- CRISPR Therapeutics (Switzerland) in its collaboration with ViaCyte focused on stem cell therapies for the treatment of diabetes
- Ginkgo Bioworks in its joint venture with Bayer (Joyn Bio) focused on plant microbiome with an initial investment of $100 million
- Ginkgo Bioworks in its $14 million partnership with Glycosyn to optimize and scale the production of human milk oligosaccharides (hMOS)
- Lysosomal Therapeutics in its exclusive option arrangement with Allergan plc with an upfront payment of $150 million
- Padlock Therapeutics in its sale to Bristol-Myers Squibb with $225 million in upfront and near-term payments
- F-star Alpha (United Kingdom) in connection with its exclusive option agreement with Bristol-Myers Squibb with payments of up to $475 million
- CRISPR Therapeutics (Switzerland) in its collaboration with Bayer (Casebia Therapeutics) valued up to $335 million up front
- Alkermes (Ireland) in the sale of its manufacturing facility and the manufacturing and royalty revenue associated with products manufactured at the facility and global rights to Recro Pharma, Inc., for $170 million
- Guerbet (France) in a $270 million acquisition of Mallinckrodt's Contrast Media and Delivery Systems business
Venture/Mezzanine Financings
- Century Therapeutics, Inc. in its launch with $250 million in financing from Bayer, Versant Ventures and Fujifilm Cellular Dynamics Inc. (FCDI), to advance to multiple programs into the clinic for hematologic and solid malignancies
- HOOKIPA Pharma (Austria) in its $37.4 million (€33.2 million) Series D financing
- Pablo Legorreta, founder and CEO of Royalty Pharma, as lead investor in ITBMed’s (Sweden) $67 million equity financing round
- 5AM Ventures as lead investor in a $45 million Series A financing of Neurogastrx
- Versant Ventures in collaboration with Bayer Healthcare in launching BlueRock Therapeutics, a next-generation regenerative medicine company, with a Series A financing of $225 million
- CRISPR Therapeutics (Switzerland) in its $140 million Series B financing
Professional Experience
Prior to rejoining Goodwin in 2014, Mr. Puopolo was a shareholder at Greenberg Traurig in Boston, where he served as co-chair of its emerging technology group. He has been licensed (inactive) in Massachusetts as a certified public accountant.
